Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Privately-held Alchemab Therapeutics, a biotech that uses the power of human immune evolution to identify and develop ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Danish drugmaker Novo Nordisk (NOV: N) has secured a significant advantage in the high-stakes obesity drug market after ...

In lawsuits reported by STAT, Eli Lilly said that the telehealth companies are falsely claiming to sell ‘personalised’ ...

Explore how Eli Lilly’s strong Q1 performance reflects ongoing trends within the S&P 500. The company’s alignment with ...